Does ELOTUZUMAB Cause Malignant neoplasm progression? 227 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 227 reports of Malignant neoplasm progression have been filed in association with ELOTUZUMAB (EMPLICITI). This represents 6.6% of all adverse event reports for ELOTUZUMAB.
227
Reports of Malignant neoplasm progression with ELOTUZUMAB
6.6%
of all ELOTUZUMAB reports
88
Deaths
77
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ELOTUZUMAB?
Of the 227 reports, 88 (38.8%) resulted in death, 77 (33.9%) required hospitalization, and 15 (6.6%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELOTUZUMAB. However, 227 reports have been filed with the FAERS database.
What Other Side Effects Does ELOTUZUMAB Cause?
Plasma cell myeloma (339)
Death (234)
Pneumonia (209)
Pyrexia (183)
Drug ineffective (137)
Neutropenia (133)
Anaemia (119)
Thrombocytopenia (107)
Diarrhoea (105)
Fatigue (95)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ELOTUZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
ELOTUZUMAB vs ELOXATIN
ELOTUZUMAB vs ELRANATAMAB
ELOTUZUMAB vs ELRANATAMAB-BCMM
ELOTUZUMAB vs ELTROMBOPAG
ELOTUZUMAB vs ELTROMBOPAG OLAMINE